Monte Rosa Therapeutics, Inc. - 8-K Filing

Monte Rosa Therapeutics announced positive Phase 1 results for MRT-8102 showing normalization of key ASCVD pathogenic drivers in subjects at elevated CVD risk. (Items: 7.01 Regulation FD DisclosureOn October 1, 2026, Monte Rosa Therapeutics, Inc, 8.01 Other EventsOn October 1, 2026, the Company announced positive data from GFORCE-1, a Phase 1 study evaluating MRT-8102, a NEK7-directed MGD b, 9.01 Financial Statements and Exhibits(d) Exhibits 99)

SEC EDGAR · October 1, 2026, 11:40 UTC

Tickers: $GLUE

Read the full article at SEC EDGAR

More Regulatory news

GROOVE BOTANICALS INC. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:24 UTC
Johnson Controls International plc - 10-K Filing SEC EDGAR · November 12, 2026, 15:24 UTC
OLD NATIONAL BANCORP /IN/ - 8-K Filing SEC EDGAR · November 12, 2026, 15:20 UTC
AMTECH SYSTEMS INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:16 UTC
REGIONAL HEALTH PROPERTIES, INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:09 UTC
Bitwise Avalanche ETF - 8-K Filing SEC EDGAR · November 12, 2026, 15:06 UTC
MiNK Therapeutics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:05 UTC
Future Vision II Acquisition Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC
THUNDER MOUNTAIN GOLD INC - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC
MiNK Therapeutics, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:49 UTC